MarketPulse

multiple sclerosis

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Tiziana Life Sciences

Tiziana's Long COVID Treatment Shows Promise in Peer-Reviewed Study

Tiziana Life Sciences reports positive preclinical data for intranasal foralumab in treating Long COVID neuroinflammation and cognitive dysfunction.
TLSAALSAlzheimer's disease
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Biogen's Three-Decade Winning Streak Under Pressure as Biosimilars Loom

Biogen's three-decade outperformance is challenged by biosimilar competition and weak growth, though new Alzheimer's and rare disease drugs offer hope. Success requires flawless execution.
BIIBESAIYbiotechrevenue growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Roche's New Blood Test for MS Neuroinflammation Gets EU Green Light

Roche receives CE mark for Elecsys NfL blood test detecting neuroinflammation in relapsing-remitting multiple sclerosis, offering minimally invasive alternative to MRI monitoring.
RHHBYmultiple sclerosispatient monitoring
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quantum BioPharma Grants 35,000 Stock Options to Retain Talent

Quantum BioPharma grants 35,000 stock options to employees at CA$6.50 strike, vesting immediately with five-year exercise window.
QNTMclinical trialbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Autolus Therapeutics Plc

Autolus Therapeutics Posts $74.3M Revenue as AUCATZYL Scales Across Europe

Autolus Therapeutics reported $74.3M in 2025 AUCATZYL revenue with UK launch underway. Company projects $120-135M in 2026 revenue and positive gross margin expansion.
AUTLFDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Medicinova, Inc.

MediciNova to Present Pipeline Progress at 2026 ROTH Conference

MediciNova executives to present clinical pipeline at March 2026 ROTH Conference, conducting direct investor meetings in Dana Point.
MNOVclinical trialsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quantum BioPharma Adjusts Debenture Terms Amid Share Price Decline

Quantum BioPharma revises debenture offering terms following share price decline, lowering conversion price to $3.00 and increasing warrant allocation.
QNTMwarrantsbiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Quantum BioPharma Launches $4M Convertible Offering to Fund Operations

Quantum BioPharma raises capital through convertible debentures and debt-to-equity conversion to strengthen balance sheet and fund business development.
QNTMprivate placementcapital raising